Randomization and treatment.
Patients were randomized to treatment arms by an interactive voice or web-based response system. Patients in cohort A were randomized in a 1:1 ratio to receive either bemnifosbuvir at a dose of 550 mg or placebo twice daily for 5 days, and patients in cohort B were randomized in a 3:1 ratio to receive either bemnifosbuvir 1,100 mg or placebo twice daily for 5 days.